Influence of E3 region on conditionally replicative adenovirus mediated cytotoxicity in hepatocellular carcinoma cells

Cancer Biology and Therapy

Volumn 8, Issue 12, 2009, Pages 1125-1132

  Lu, Qin ^a,b   Yu, De Hong ^a   Fang, Chao ^a   Liu, Fang ^a   Ye, Xun ^a,b   Zhao, Yi ^b   Qin, Jie ^b   Guo, Xiao Kui ^a   Liang, Min ^b   Hu, Fang ^b   Chen, Hong Zhuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Sunway Biotech Co Ltd   (China)

Author keywords

CRAd; E3; Hep3B; Hepatocellular carcinoma; Mitochondrial membrane potential; TRAIL; Virotherapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; CONDITIONALLY REPLICATING ADENOVIRUS; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL DEATH; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 68049120436     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.12.8445     Document Type: Article

References (26)

1. Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med 2008; 29:130-43.
2. Galle PR. Sorafenib in advanced hepatocellular carcinoma - we have won a battle not the war. J Hepatol 2008; 49:871-3.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90.
5. Zhang H, Wang H, Zhang J, Qian G, Niu B, Fan X, et al. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther 2009; 17:57-64.
6. Ye X, Lu Q, Zhao Y, Ren Z, Ren XW, Qiu QH, et al. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Int J Mol Med 2005; 16:1179-84.
7. Gomez-Navarro J, Curiel DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 2000; 1:148-58.
8. Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 2004; 6:172-83.
9. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol 2004; 23:75-111.
10. Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano H, et al. Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 2005; 26:1273-81.
11. Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med 2002; 34:114-22.
12. Yamamoto T, Nagano H, Sakon M, Wada H, Eguchi H, Kondo M, et al. Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/ TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. Clin Cancer Res 2004; 10:7884-95.
13. Hu B, Zhu H, Qiu S, Su Y, Ling W, Xiao W, et al. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. Biochem Biophys Res Commun 2004; 325:1153-62.
14. Routes JM, Ryan S, Clase A, Miura T, Kuhl A, Potter TA, et al. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J Immunol 2000; 165:4522-7.
15. Zhao H, Xu YH. Mad-overexpression downregulates the malignant growth and p53 mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res 1999; 9:51-9.
16. Zhao DH, Hong JJ, Guo SY, Yang RL, Yuan J, Wen CJ, et al. Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402. Cell Res 2004; 14:74-80.
17. Abraham TM, Lewellyn EB, Haines KM, Loeb DD. Characterization of the contribution of spliced RNAs of hepatitis B virus to DNA synthesis in transfected cultures of Huh7 and HepG2 cells. Virology 2008; 379:30-7.
18. Ye X, Lu Q, Zhao Y, Ren Z, Meng X, Ge SF, et al. Assessment of a capsid-modified E1B 55-kDa protein-deficient adenovirus vector for tumor treatment. Prog Biochem Biophys 2005; 32:1156-64.
19. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6:29-40.
20. Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, et al. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression. Oncogene 2000; 19:4604-10.
21. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335-46.
22. Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277:768.
23. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263:14-25.
24. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8:3348-59.
25. Danielsson A, Dzojic H, Nilsson B, Essand M. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther 2008; 15:203-13.
26. Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005; 12:61-71.